Amitkumar Mehta, MD, is an associate professor and associate scientist at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). He is the director of the Lymphoma and CAR-T program at UAB. Dr. Mehta is a board-certified hematologist and oncologist with a special interest in lymphomas, including B and T-cell lymphoma, cutaneous T-cell lymphoma, and immune effector cell therapy. He is also a clinical investigator with a special interest in developing non-chemotherapy approaches to treating lymphoma, including immunotherapy, CAR-T therapy, immune-modulating therapy, and targeted therapy.
Dr. Mehta is a principal investigator of innovative clinical trials for the treatment of lymphoma at UAB. He is also involved in lymphoma-related research, which includes genomic and proteomic (gene- and protein-related) studies in various kinds of lymphomas. As a clinical investigator, he is part of many clinical trials as principal investigator or sub-investigator. Dr. Mehta seeks to develop targeted and immunologic therapies in lymphoma with fewer toxicities and more effectiveness.
Dr. Mehta completed a fellowship at the University of Alabama at Birmingham Hospital and his residency at George Washington University Hospital. He earned his medical degree from Baroda Medical College in Vadodara, India.